Oral Health Group

Zoledronic Acid Reduces Symptomatic Periodontal Disease In Osteoporosis Patients

August 30, 2019
by MDedge

Zoledronic acid was effective at preventing symptomatic periodontal disease in patients with osteoporosis and good oral hygiene, according to Akira Taguchi, DDS, PhD, of the department of oral and maxillofacial radiology at Matsumoto Dental University, Nagano, Japan, and associates.

In a study published in Menopause, the investigators retrospectively analyzed 542 men and women with osteoporosis who participated in the randomized ZONE (Zoledronate Treatment in Efficacy to Osteoporosis) trial. Patients received either zoledronic acid (n = 258) or placebo (n = 284) once yearly for 2 years by IV infusion; mean age was 74 years in both groups. Patients were instructed to maintain good oral health at baseline and every 3 months afterward. Participants with signs or symptoms involving the oral cavity at the follow-up approximately every 3 months were referred to dentists for examination of oral disease.

To view the full story, please click here.

RELATED ARTICLE: Minimally Invasive Diagnostic Tools in the Diagnosis of Periodontal Disease

Print this page


Have your say:

Your email address will not be published.